Yong Song

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai Shi, Li Zhang, Xiaoqing Liu et al. · The Lancet Oncology · 2013 · 420 citations

Double-blind Phase 3, Medicine, Metronomic Therapy +9

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 376 citations · Full text

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Yuankai Shi, L. Wang, Baohui Han et al. · Annals of Oncology · 2017 · 333 citations

Advanced Lung Disease, Medicine, Pathology +9

Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non‑small cell lung cancer

Jianwei Gao, Xiangyu Qiu, Guangmin Xi et al. · Oncology Reports · 2018 · 277 citations · Full text

Gsdmd Protein Levels, Inflammatory Lung Disease, Lung Inflammation +20

Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer

Tangfeng Lv, Dongmei Yuan, Xiaohui Miao et al. · PLoS ONE · 2012 · 266 citations · Full text